Lynda Charters

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

Efavirenz boosts cholesterol turnover in retina, brain.

Data on Palatin’s formulation PL9643 indicates clinical efficacy across multiple signs and symptoms of dry eye disease without sacrificing safety and tolerability.

The study found that pseudophakic children older at the time of surgery developed a glaucoma-related adverse event less frequently.

The results showed that current smokers had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression, strabismus surgery, and eyelid recession.

One way to advance the current understanding of GA is to study how disease progression varies among related individuals.

Physicians should continue to have conversations and assessments of patients with glaucoma before the decision is reached to stop driving.

The authors conducted a prospective non-interventional study in which a self-questionnaire was used to evaluate the ocular symptoms and medical background of patients with KC and OSD who engage in chronic eye rubbing.

An important take-away was the total and central corneal staining score improving after only 2 weeks of treatment.

Atropine 0.01% eye drops decreased myopia progression in children over the study course of 1 year.

Based on the initial ophthalmic findings, it is difficult but important to predict the patients’ progression to a specific level of disease severity.

The researchers undertook a retrospective, comparative, consecutive case series of patients with endophthalmitis after open globe injury.

The investigators conducted a retrospective cross-sectional analysis to determine the epidemiologic pattern of IPV–related ocular injuries in US adults

The primary outcome was an association between alcohol misuse and corneal endothelial metrics.

Though there is no current FDA-approved treatment, lotilaner ophthalmic solution, 0.25%, is the first drug designed to treat and target the underlying cause of Demodex blepharitis.

Because the disease is vision-threatening, the investigators retrospectively reviewed the demographic, clinical, and surgical data from the cases of patients who required additional CXL.

Investigators reported that moderate to severe Meibomian gland dysfunction (MGD) was treated successfully with a 3-week course of weekly oral azithromycin that was equivalent to a 6-week course of oral doxycyclin.

In this first study to provide an in-depth analysis of the retinal proteins, researchers conducted histopathologic and biochemical studies of postmortem retina and brain tissues from 86 human donors.

Self-reported survey data “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported.

Investigators evaluated risuteganib for safety and effectiveness in patients with dry AMD.

Researchers retrospectively analyzed the longitudinal clinical data of 117 eyes of 106 Caucasian patients with high myopia MNV treated with intravitreal bevacizumab injections.

Conference aims to promote professional education and scientific development in corneal ectasias.

Investigators evaluated and compared the long-term formation of posterior capsular opacification (PCO) and the rate of glistenings that developed between 2 hydrophobic acrylic intraocular lenses (IOLs).

Smaller corneal incisions made during cataract surgery are linked with better visual outcomes and less frequent postoperative endophthalmitis.

The FDA issued an update to the warning issued early in February and recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment, and the firm agreed to initiate a recall.

The Biologics License Application for aflibercept 8 mg was supported by positive data from the PULSAR study, investigating wet AMD, and the PHOTON study, investigating DME.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.

According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.